Publicaciones (87) Publicaciones de Rubén Hernández Alcoceba

2023

  1. Application of a split-Cre system for high-capacity adenoviral vector amplification

    Biotechnology Journal, Vol. 18, Núm. 3

  2. Engineering U1-Based Tetracycline-Inducible Riboswitches to Control Gene Expression in Mammals

    ACS Nano, Vol. 17, Núm. 23, pp. 23331-23346

  3. Preferential expression of SCN1A in GABAergic neurons improves survival and epileptic phenotype in a mouse model of Dravet syndrome

    Journal of Molecular Medicine, Vol. 101, Núm. 12, pp. 1587-1601

  4. Viral vector–mediated expression of NaV1.1, after seizure onset, reduces epilepsy in mice with Dravet syndrome

    Journal of Clinical Investigation, Vol. 133, Núm. 12

2022

  1. Broad virus inactivation using inorganic micro/nano-particulate materials

    Materials Today Bio, Vol. 13

  2. Galectin-3 inhibition boosts the therapeutic efficacy of Semliki Forest virus in pediatric osteosarcoma

    Molecular Therapy - Oncolytics, Vol. 26, pp. 246-264

  3. High value of 64Cu as a tool to evaluate the restoration of physiological copper excretion after gene therapy in Wilson's disease

    Molecular Therapy - Methods and Clinical Development, Vol. 26, pp. 98-106

  4. Oncolytic DNX-2401 Virus for Pediatric Diffuse Intrinsic Pontine Glioma

    New England Journal of Medicine, Vol. 386, Núm. 26, pp. 2471-2481

  5. Preclinical model for phenotypic correction of dystrophic epidermolysis bullosa by in vivo CRISPR-Cas9 delivery using adenoviral vectors

    Molecular Therapy - Methods and Clinical Development, Vol. 27, pp. 96-108

2021

  1. Author Correction: Epilepsy and neuropsychiatric comorbidities in mice carrying a recurrent Dravet syndrome SCN1A missense mutation (Scientific Reports, (2019), 9, 1, (14172), 10.1038/s41598-019-50627-w)

    Scientific Reports

  2. Gene supplementation of CYP27A1 in the liver restores bile acid metabolism in a mouse model of cerebrotendinous xanthomatosis

    Molecular Therapy - Methods and Clinical Development, Vol. 22, pp. 210-221

  3. Gene therapies and COVID-19 vaccines: a necessary discussion in relation with viral vector-based approaches

    Orphanet Journal of Rare Diseases

  4. Local administration of IL-12 with an HC vector results in local and metastatic tumor control in pediatric osteosarcoma

    Molecular Therapy - Oncolytics, Vol. 20, pp. 23-33

  5. Transfer of SCN1A to the brain of adolescent mouse model of Dravet syndrome improves epileptic, motor, and behavioral manifestations

    Molecular Therapy - Nucleic Acids, Vol. 25, pp. 585-602

  6. Understanding the molecular mechanism of mir-877-3p could provide potential biomarkers and therapeutic targets in squamous cell carcinoma of the cervix

    Cancers, Vol. 13, Núm. 7

  7. Understanding the potential role of sirtuin 2 on aging: Consequences of sirt2.3 overexpression in senescence

    International Journal of Molecular Sciences, Vol. 22, Núm. 6, pp. 1-23

2020

  1. Alterations of the Hippocampal Neurogenic Niche in a Mouse Model of Dravet Syndrome

    Frontiers in Cell and Developmental Biology, Vol. 8

  2. High-capacity adenoviral vectors: Expanding the scope of gene therapy

    International Journal of Molecular Sciences, Vol. 21, Núm. 10

2019

  1. Danio rerio as model organism for adenoviral vector evaluation

    Genes, Vol. 10, Núm. 12

  2. Epilepsy and neuropsychiatric comorbidities in mice carrying a recurrent Dravet syndrome SCN1A missense mutation

    Scientific Reports, Vol. 9, Núm. 1